DEADLINE: September 5th, **Letter of intent is due two weeks prior to deadline
ACCELERATING DRUG DISCOVERY for FRONTOTEMPORAL DEGENERATION RFP: The Alzheimer's Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD) are partnering together to issue this RFP to seek to accelerate and support drug discovery for FTD and related disorders. See full RFP here.
BIOMARKER-BASED TARGET ENGAGEMENT STUDIES to SUPPORT CLINICAL DEVELOPMENT of NOVEL THERAPEUTICS for ALZHEIMER'S DISEASE RFP: The Alzheimer's Drug Discovery Foundation (ADDF) and the Alzheimer's Disease Cooperative Study (ADCS) are collaborating to support pilot biomarker-based clinical trials of novel therapeutics for Alzheimer's disease. See full RFP here.
DEADLINES for other 2014 RFPs:
**Letter of intent is due two weeks prior to deadline
PRECLINICAL DRUG DISOCVERY RFP: The Alzheimer's Drug Discovery Foundation (ADDF) seeks to fill the critical translational funding gap between basic research and later stage drug development by funding promising preclinical drug discovery and biomarker development programs relevant to Alzheimer's disease, other dementias and cognitive againg. See full RFP here.
PACT RFP: The ADDF has created the Program to Accelerate Clinical Trials (PACT) to increase the number of innovative drugs tested in humans at the crucial proof of concept stage for Alzheimer’s disease. This program will fund biomarker-based, proof-of-concept pilot clinical trials for Alzheimer’s. 2014 deadlines for full proposals are March 5, June 5, September 5 and December 5. LOIs are due at least two weeks prior to the proposal deadlines. See full RFP here.
ADDF/NIH RFP: The ADDF will consider financial assistance for relevant NIH grant applications that were scored but not funded in response to certain NIH funding opportunities. Application deadline is rolling. See full RFP here.